Effects of Prescription Omega-3 Acids on Glucose and Lipoprotein Lipids in Subjects With Hypertriglyceridemia

This trial will utilize a randomized, double-blind, two-period crossover design. At Visit 2
(Week 0), subjects meeting all entry criteria will be randomized to one of two treatment
sequences: placebo or prescription omega-3 acid ethyl esters for the first 6 week phase
followed by the study product they did not receive during the first phase (prescription
omega-3 acid ethyl esters or placebo) for the second 6 weeks.

Inclusion Criteria:

- Men and postmenopausal women, ages 18-79 years.

- Fasting, triglyceride (TG)level in the borderline high to high range.

- Fasting, low density lipoprotein cholesterol (LDL-C)below the very high range while
on no lipid altering therapy or while taking stable-dose statin therapy

- Provide written informed consent and authorization for protected health information

Exclusion Criteria:

- Use of any lipid-altering medications, which cannot be stopped, except stable dose
statin therapy.

- Use of any omega-3 fatty acid ethyl ester medications or dietary supplements with
>1.0 g/d of EPA,DHA, or a combination of EPA and DHA

- CHD or a CHD risk equivalent

- Body mass index over 45 kg per square meter

- Allergy or sensitivity to omega-3 fatty acids, corn or corn products (e.g., corn
oil), D-alpha tocopherol (vitamin E) or any ingredients in the study drug

- Certain muscle, liver, kidney, lung or gastrointestinal conditions

- Poorly controlled hypertension

- Certain medications

- Active cancers treated within prior 2 years (except non-melanoma skin cancer)